Blinatumomab Utilization in Pediatric B-Cell Acute Lymphoblastic Leukemia: Experience From the Mountain West
Pediatric leukemia patients in remote areas successfully received complex immunotherapy at home, making intensive cancer treatment more accessible.
Fifty pediatric B-ALL patients in the Mountain West, some living over 600 miles from the treating hospital, successfully received blinatumomab via an outpatient home infusion protocol with 96% local service delivery. The model demonstrates that structured home healthcare partnerships, prior authorization, and standardized protocols make outpatient blinatumomab feasible, safe, and cost-efficient.
What the study was
- Study design
- Prospective single-center care delivery analysis
- Population
- Pediatric and young adult B-ALL patients ages 1–23 (Mountain West US, up to 640 miles from institution)
- Sample size
- 50
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Pediatric Blood & Cancer
Why it surfaced
Practical care-delivery evidence for outpatient blinatumomab in pediatric B-ALL addressing access gaps in rural/remote regions. Blinatumomab is established therapy; this is novel implementation evidence with near-term replicability for other pediatric oncology centers.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.